Which client is most at risk for hospital-acquired methicillin-resistant Staphylococcus aureus

1. Boyce JM. Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. Eur J Clin Microbiol Infect Dis. 1994;13(1):45–49. [PubMed] [Google Scholar]

2. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clin Infect Dis. 2006;42(3):389–391. [PubMed] [Google Scholar]

3. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763–1771. [PubMed] [Google Scholar]

4. Boyce JM. Understanding and controlling methicillin-resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol. 2002;23(9):485–487. [PubMed] [Google Scholar]

5. Boyce JM. Increasing prevalence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol. 1990;11(12):639–642. [PubMed] [Google Scholar]

6. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 2002;162(19):2229–2235. [PubMed] [Google Scholar]

7. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–59. [PubMed] [Google Scholar]

8. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26(2):166–174. [PubMed] [Google Scholar]

9. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004;39(6):776–782. [PubMed] [Google Scholar]

10. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med. 2001;344(1):11–16. [PubMed] [Google Scholar]

11. Muller A, Mauny F, Talon D, Donnan PT, Harbarth S, Bertrand X. Effect of individual- and group-level antibiotic exposure on MRSA isolation: a multilevel analysis. J Antimicrob Chemother. 2006;58(4):878–881. [PubMed] [Google Scholar]

12. Warren DK, Guth RM, Coopersmith CM, Merz LR, Zack JE, Fraser VJ. Epidemiology of methicillin-resistant Staphylococcus aureus colonization in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2006;27(10):1032–1040. [PubMed] [Google Scholar]

13. Fishbain JT, Lee JC, Nguyen HD, et al. Nosocomial transmission of methicillin-resistant Staphylococcus aureus: a blinded study to establish baseline acquisition rates. Infect Control Hosp Epidemiol. 2003;24(6):415–421. [PubMed] [Google Scholar]

14. Marshall C, Wolfe R, Kossmann T, Wesselingh S, Harrington G, Spelman D. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by trauma patients in the intensive care unit. J Hosp Infect. 2004;57(3):245–252. [PubMed] [Google Scholar]

15. Hashimoto M, Sugawara Y, Tamura S, et al. Acquisition of methicillin-resistant Staphylococcus aureus after living donor liver transplantation: a retrospective cohort study. BMC Infect Dis. 2008;8:155. [PMC free article] [PubMed] [Google Scholar]

16. Moore C, Dhaliwal J, Tong A, et al. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) acquisition in roommate contacts of patients colonized or infected with MRSA in an acute-care hospital. Infect Control Hosp Epidemiol. 2008;29(7):600–606. [PubMed] [Google Scholar]

17. Ibelings MM, Bruining HA. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg. 1998;164(6):411–418. [PubMed] [Google Scholar]

18. Rioux C, Armand-Lefevre L, Guerinot W, Andremont A, Lucet JC. Acquisition of methicillin-resistant Staphylococcus aureus in the acute care setting: incidence and risk factors. Infect Control Hosp Epidemiol. 2007;28(6):733–736. [PubMed] [Google Scholar]

19. Yount RJ, Vries JK, Councill CD. The Medical Archival System: an information retrieval system based on distributed parallel processing. Inf Process Manag. 1991;27:379–389. [Google Scholar]

20. Cook DJ, Kollef MH. Risk factors for ICU-acquired pneumonia. JAMA. 1998;279(20):1605–1606. [PubMed] [Google Scholar]

21. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(suppl 5):S378–S385. [PubMed] [Google Scholar]

22. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis. 2003;9(11):1415–1422. [PMC free article] [PubMed] [Google Scholar]

23. LeBlanc L, Pepin J, Toulouse K, et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2006;12(9):1398–1405. [PMC free article] [PubMed] [Google Scholar]

24. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother. 2008;61(1):26–38. [PubMed] [Google Scholar]

25. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960. [PubMed] [Google Scholar]

26. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308–2313. [PubMed] [Google Scholar]

27. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis. 2003;36(2):149–158. [PubMed] [Google Scholar]

28. Owens RC, Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S19–S31. [PubMed] [Google Scholar]

29. Merrer J, Santoli F, Appere de Vecchi C, Tran B, De Jonghe B, Outin H. “Colonization pressure” and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol. 2000;21(11):718–723. [PubMed] [Google Scholar]

Page 2

Univariate Analysis of Demographic and Admission Characteristics of Patients Who Acquired Methicillin-Resistant Staphylococcus aureus during Hospitalization and Matched Control Patients

Variable	Case patients (n = 451)	Control patients (n = 866)	OR (95% CI)	P
Age, years, mean ± SD	60.2 ± 17.5	59.2 ± 16.4	1.00 (1.00–1.01)	.35
Male sex	250 (55.4)	484 (55.9)	0.95 (0.75–1.20)	.67
Race				.98
White	330 (73.2)	639 (73.8)	1.00
Black	42 (9.3)	79 (9.1)	1.02 (0.69–1.52)
Other or unknown	79 (17.5)	148 (17.1)	1.02 (0.75–1.41)
Emergent or urgent admission	401 (88.9)	767 (88.6)	1.06 (0.73–1.55)	.75
Admission from long-term care facility	41 (9.1)	51 (5.9)	1.52 (0.99–2.35)	.06
Admitting service				.52
Medical	260 (57.6)	520 (60.0)	1.00
Surgical	183 (40.6)	329 (38.0)	1.18 (0.88–1.58)
Other	8 (1.8)	17 (2.0)	0.92 (0.38–2.24)
LOS, days, median (IQR)	30 (17–50)	32 (20–54)	1.00 (1.00–1.00)	.51
Prior to index culture	12 (6–24)	13 (8–24)	1.00 (1.00–1.00)	.98
In target unit	21 (12–35)	21 (12–34)	1.00 (1.00–1.00)	.29
Target unit stay prior to index culture	447 (99.1)	821 (94.8)	6.27 (2.23–17.61)	<.001
LOS in target unit prior to index culture, days, median (IQR)	9 (5–18)	10 (5–19)	1.00 (1.00–1.00)	.65
Other UPMC hospitalization during past 6 months	100 (22.2)	241 (27.8)	0.73 (0.56–0.95)	.02
Substance abuse or dependence
Alcohol	42 (9.3)	95 (11.0)	0.84 (0.57–1.23)	.37
Drug	23 (5.1)	40 (4.6)	1.16 (0.68–1.99)	.58
Tobacco	35 (7.8)	72 (8.3)	0.89 (0.58–1.38)	.61
Primary diagnosisa				.08
Cardiocirculatory disease	51 (11.3)	135 (15.6)	1.00
Respiratory disease	100 (22.2)	146 (16.9)	2.00 (1.26–3.17)
Digestive tract disease	48 (10.7)	86 (9.9)	1.59 (0.94–2.68)
Cerebrovascular disease	38 (8.4)	71 (8.2)	1.64 (0.87–3.06)
Injury or trauma	98 (21.8)	186 (21.5)	1.54 (0.97–2.45)
Other diagnosisb	115 (25.6)	242 (27.9)	1.38 (0.89–2.15)
Age-adjusted Charlson comorbidity index, mean ± SD	3.8 ± 2.9	4.0 ± 3.0	0.97 (0.93–1.01)	.13
Total point value assigned for abnormal laboratory values,c median (IQR)	5 (4–6)	5 (4–6)	0.95 (0.87–1.03)	.18
Contact isolation for other target organism	161 (35.7)	339 (39.1)	0.83 (0.64–1.07)	.14
Discharge disposition				.15
Alive	286 (63.4)	539 (62.2)	1.00
Deceased	112 (24.8)	193 (22.3)	1.10 (0.83–1.46)
Unknown	53 (11.8)	134 (15.5)	0.74 (0.52–1.06)